α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells

Neuroscience Letters

Volumn 507, Issue 2, 2012, Pages 133-136

  Tousi, Neda Saffarian ^a   Buck, Daniel J ^a   Curtis, J Thomas ^a   Davis, Randall L ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Synuclein; Astrocyte; Chemokine; Neuroinflammation; NF B; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; MESSENGER RNA;

ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; INFLAMMATION; MACROGLIA; NERVE DEGENERATION; NEURITIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ALPHA-SYNUCLEIN; ASTROCYTES; CELL LINE, TUMOR; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-1BETA; NF-KAPPA B; PARKINSON DISEASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84855328900     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.12.001     Document Type: Article

References (52)

1. Barnum C.J., Eskow K.L., Dupre K., Blandino P., Deak T., Bishop C. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 2008, 156:30-41.
2. Beyer K., Ispierto L., Latorre P., Tolosa E., Ariza A. Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. J. Neurol. Sci. 2011.
3. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 1995, 202:17-20.
4. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998, 21:249-254.
5. Croisier E., Graeber M.B. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol. 2006, 112:517-530.
6. Davis R.L., Buck D.J., Saffarian N., Mohan S., DeSilva U., Fernando S.C., Stevens C.W. Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J. Neuroimmune Pharmacol. 2008, 3:150-153.
7. Davis R.L., Buck D.J., Saffarian N., Stevens C.W. The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J. Neuroimmunol. 2007, 186:141-149.
8. Davis R.L, Dertien J., Syapin P.J. Ethanol-induced modulation of inducible nitric-oxide synthase activity in human A172 astrocytoma cells. Alcohol. Clin. Exp. Res. 2002, 26:1404-1411.
9. Dong Y., Benveniste E.N. Immune function of astrocytes. Glia 2001, 36:180-190.
10. Forno L.S., DeLanney L.E., Irwin I., Di Monte D., Langston J.W. Astrocytes and Parkinson's disease. Prog. Brain Res. 1992, 94:429-436.
11. Gao H.M., Zhang F., Zhou H., Kam W., Wilson B., Hong J.S. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ. Health Perspect. 2010, 119:807-814.
12. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
13. Henning J., Strauss U., Wree A., Gimsa J., Rolfs A., Benecke R., Gimsa U. Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease. Neurosci. Res. 2008, 62:246-253.
14. Hettinger A.M., Allen M.R., Zhang B.R., Goad D.W., Malayer J.R., Geisert R.D. Presence of the acute phase protein, bikunin, in the endometrium of gilts during estrous cycle and early pregnancy. Biol. Reprod. 2001, 65:507-513.
15. Hirsch E.C, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
16. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S9-S15.
17. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 1999, 19:3440-3447.
18. Jin J., Li G.J., Davis J., Zhu D., Wang Y., Pan C., Zhang J. Identification of novel proteins associated with both alpha-synuclein and DJ-1. Mol. Cell. Proteomics 2007, 6:845-859.
19. Khanlou N., Moore D.J., Chana G., Cherner M., Lazzaretto D., Dawes S., Grant I., Masliah E., Everall I.P. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J. Neurovirol. 2009, 15:131-138.
20. Klegeris A., Giasson B.I., Zhang H., Maguire J., Pelech S., McGeer P.L. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 2006, 20:2000-2008.
21. Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflamm. 2008, 5:8.
22. Kosel S., Egensperger R., von Eitzen U., Mehraein P., Graeber M.B. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. 1997, 93:105-108.
23. Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. {alpha}-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 2009, 284:10211-10222.
24. Lee H.J., Kim C., Lee S.J. Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection. Oxid. Med. Cell. Longev. 2010, 3:283-287.
25. Lee H.J., Lee S.J. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 2002, 277:48976-48983.
26. Lee H.J., Suk J.E., Patrick C., Bae E.J., Cho J.H., Rho S., Hwang D., Masliah E., Lee S.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 2010, 285:9262-9272.
27. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol. 2009, 89:277-287.
28. Lu J.Q., Fan Y., Mitha A.P., Bell R., Metz L., Moore G.R., Yong V.W. Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 2009, 68:179-189.
29. Maier A., Zimmermann C., Beglinger C., Drewe J., Gutmann H. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br. J. Pharmacol. 2007, 150:361-368.
30. Miklossy J., Doudet D.D., Schwab C., Yu S., McGeer E.G., McGeer P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2006, 197:275-283.
31. Minagar A., Shapshak P., Fujimura R., Ownby R., Heyes M., Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 2002, 202:13-23.
32. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
33. Norris E.H., Giasson B.I., Lee V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 2004, 60:17-54.
34. Rappold P.M., Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010, 7:413-423.
35. Rivieccio M.A., John G.R., Song X., Suh H.S., Zhao Y., Lee S.C., Brosnan C.F. The cytokine IL-1beta activates IFN response factor 3 in human fetal astrocytes in culture. J. Immunol. 2005, 174:3719-3726.
36. Sanders V.J., Pittman C.A., White M.G., Wang G., Wiley C.A., Achim C.L. Chemokines and receptors in HIV encephalitis. AIDS 1998, 12:1021-1026.
37. Shanmugam N., Ransohoff R.M., Natarajan R. Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. J. Biol. Chem. 2006, 281:31212-31221.
38. Sheng W.S., Hu S., Min X., Cabral G.A., Lokensgard J.R., Peterson P.K. Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005, 49:211-219.
39. Stefanova N., Klimaschewski L., Poewe W., Wenning G.K., Reindl M. Glial cell death induced by overexpression of alpha-synuclein. J. Neurosci. Res. 2001, 65:432-438.
40. Sun D., Ding A. MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nat. Immunol. 2006, 7:375-381.
41. Tanuma N., Sakuma H., Sasaki A., Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2006, 112:195-204.
42. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
43. Tousi N.S., Buck D.J., Zecca L., Davis R.L. Neuromelanin inhibits CXCL10 expression in human astroglial cells. Neurosci. Lett. 2010, 486:47-50.
44. Vekrellis K., Rideout H.J., Stefanis L. Neurobiology of alpha-synuclein. Mol. Neurobiol. 2004, 30:1-21.
45. Venda L.L., Cragg S.J., Buchman V.L., Wade-Martins R. alpha-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2004, 33:559-568.
46. Williams R., Dhillon N.K., Hegde S.T., Yao H., Peng F., Callen S., Chebloune Y., Davis R.L., Buch S.J. Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia 2009, 57:734-743.
47. Williams R., Yao H., Peng F., Yang Y., Bethel-Brown C., Buch S. Cooperative induction of CXCL10 involves NADPH oxidase: Implications for HIV dementia. Glia 2010, 58:611-621.
48. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8:600-606.
49. Yao Y., Kubota T., Sato K., Takeuchi H., Kitai R., Matsukawa S. Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells. J. Neurooncol. 2005, 72:217-223.
50. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., Suzuki K., Fujita S. The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J. Neuroimmunol. 2008, 204:43-51.
51. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.
52. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 2002, 926:42-50.